15 results on '"Mamta, K."'
Search Results
2. Persistent low prevalence of hepatitis B vaccination among people with HIV: Time for a change?
- Author
-
Garcia, Angie, Vigil, Karen J., Taylor, Barbara, Kshirsagar, Onkar, Thamer, Mae, and Jain, Mamta K.
- Subjects
HEPATITIS B vaccines ,DISEASE prevalence ,HEPATITIS B virus ,HIV ,HIV-positive persons ,HIV infection transmission ,HEPATITIS B - Abstract
Hepatitis B virus (HBV) infection is one of the leading causes of hepatocellular carcinoma and mortality among people living with HIV (PLWH). HBV vaccination provides protection from infection; however, vaccination rates are low. We conducted a retrospective analysis at three HIV centres in Texas to determine the proportion of PLWH who received the recommended 3 doses of hepatitis B vaccine within 1 year. Factors associated with vaccination completion were explored. In our sample of three sites in a state with high HIV transmission and high rates of liver disease from 2011 to 2021, showed low rates of hepatitis B vaccination. Among eligible PLWH, only 9% completed the 3‐dose hepatitis B vaccine series in 1 year. There is an urgent need to improve HBV vaccination to reach 2030 target for hepatitis B elimination. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
3. Predictors of linkage to hepatitis C virus care among people living with HIV with hepatitis C infection and the impact of loss to HIV follow‐up.
- Author
-
Lau, Abby A., Strebe, Joslyn K., Sura, Teena V., Hansen, Laura A., and Jain, Mamta K.
- Subjects
HEPATITIS C virus ,HIV-positive persons ,HEPATITIS C ,NEEDLE exchange programs ,HIV ,PATIENT dropouts - Abstract
Objective: Half of the people living with HIV (PLWH) with hepatitis C virus (HCV) remain untreated for HCV. We examined predictors of HCV linkage to care among PLWH and the impact of HIV lost to care. Design and methods: We conducted a retrospective review of PLWH/HCV from our HIV clinics between 2014 and 2017, and examined predictors of HCV linkage to care. We used the Kaplan–Meier method to estimate the probability of HIV retention and HCV linkage over time. Results: Of 615 PLWH/HCV, 34% linked to HCV care and 21% were cured. Higher odds of linkage to HCV care were among blacks (adjusted odds ratio [aOR]: 2.95, 95% confidence interval [CI]: 1.59, 5.47), prior injection drug users (IDUs; aOR: 2.89, 95% CI: 1.39, 6.01), Medicare (aOR: 3.09, 95% CI: 1.56, 6.11), and cirrhotics (aOR: 2.80, 95% CI: 1.52, 5.14). Reduced odds for linkage were in active IDU (aOR: 0.16, 95% CI: 0.05, 0.45) and those seen by an advanced practice provider (aOR: 0.53, 95% CI: 0.30, 0.92). The main reason for failure to link to HCV care was lost to HIV care. At 3 years, the overall probability of being retained in HIV care was 53%; among those who had an HCV evaluation visit, it was 75% vs. 41% with no HCV evaluation visit. Accounting for loss to follow‐up, PLWH/HCV had a 65% probability of having an HCV evaluation at 3 years. Statement of significance: HCV is a curable infection in those with or without HIV. Yet, high proportions of people living with HIV with HCV remain untreated for HCV, leading to complications of liver disease and death. Our study found that only one‐third of HIV/HCV patients were linked to HCV care. The main reason for not linking to HCV care was that increasing numbers of patients drop out of HIV care over time. Our study suggests that early focus on HCV treatment would increase the number of patients cured, but it is unclear whether this would impact retention in HIV care. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
4. Initiation of Antiretroviral Therapy in the Hospital Is Associated With Linkage to Human Immunodeficiency Virus (HIV) Care for Persons Living With HIV and Substance Use Disorder.
- Author
-
Jacobs, Petra, Feaster, Daniel J, Pan, Yue, Gooden, Lauren K, Daar, Eric S, Lucas, Gregory M, Jain, Mamta K, Marsh, Eliza L, Armstrong, Wendy S, Rodriguez, Allan, Rio, Carlos del, and Metsch, Lisa R
- Subjects
HIV infections ,HIV-positive persons ,HOSPITALS ,SUBSTANCE abuse ,TIME ,HIGHLY active antiretroviral therapy ,DESCRIPTIVE statistics ,SECONDARY analysis - Abstract
Background Studies have demonstrated benefits of antiretroviral therapy (ART) initiation on the day of human immunodeficiency virus (HIV) testing or at first clinical visit. The hospital setting is understudied for immediate ART initiation. Methods CTN0049, a linkage-to-care randomized clinical trial, enrolled 801 persons living with HIV (PLWH) and substance use disorder (SUD) from 11 hospitals across the United States. This secondary analysis examined factors related to initiating (including reinitiating) ART in the hospital and its association with linkage to HIV care, frequency of outpatient care visits, retention, and viral suppression. Results Of 801 participants, 124 (15%) initiated ART in the hospital, with more than two-thirds of these participants (80/124) initiating ART for the first time. Time to first HIV care visit among those who initiated ART in the hospital and those who did not was 29 and 54 days, respectively (P =.0145). Hospital initiation of ART was associated with increased frequency of HIV outpatient care visits at 6 and 12 months. There was no association with ART initiation in the hospital and retention and viral suppression over a 12-month period. Participants recruited in Southern hospitals were less likely to initiate ART in the hospital (P <.001). Conclusions Previous research demonstrated benefits of immediate ART initiation, yet this approach is not widely implemented. Research findings suggest that starting ART in the hospital is beneficial for increasing linkage to HIV care and frequency of visits for PLWH and SUD. Implementation research should address barriers to early ART initiation in the hospital. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
5. Incidence and Predictors of Hepatitis B Surface Antigen Clearance in HIV Patients: A Retrospective Multisite Study.
- Author
-
Jain, Mamta K, Vigil, Karen J, Parisot, Paul, Go, Gabriella, Vu, Trung, Li, Xilong, Hansen, Laura, and Taylor, Barbara S
- Subjects
- *
HEPATITIS associated antigen , *DRUG abuse , *HIV-positive persons , *CHRONIC hepatitis B , *FORECASTING , *HEPATITIS B virus , *PNEUMOCYSTIS pneumonia - Abstract
Background New therapies to achieve hepatitis B surface antigen (HBsAg) clearance are under development. However, gaps in knowledge exist in understanding the incidence and predictors of HBsAg clearance in a racially diverse HIV population. Methods We examined the incidence and risk of HBsAg clearance in a retrospective cohort of people with HIV/hepatitis B virus (HBV). Included patients had sufficient data to establish chronic infection based on Centers for Disease Control and Prevention guidelines. We examined the incident rate for HBsAg loss and hazard rate ratios to evaluate predictors for HBsAg clearance in a multivariable model. Results Among 571 HIV/HBV patients, 87% were male, 61% were Black, 45% had AIDS, 48% were HBeAg positive, and the median follow-up was 88 months. Incident HBsAg clearance was 1.5 per 100 person-years. In the multivariate model, those with AIDS at baseline (adjusted hazard ratio [aHR], 2.43; 95% CI, 1.37–4.32), Hispanics (aHR, 3.57; 95% CI, 1.33–9.58), and those with injection drug use as an HIV risk factor (aHR, 3.35; 95% CI, 1.26–8.89) were more likely to lose HBsAg, whereas those who were HBeAg positive (aHR, 0.34; 95% CI, 0.19–0.63) were less likely to lose HBsAg. The median change in CD4 cell count during the observation period was 231 cells/mm3 in those with HBsAg loss vs 112 cells/mm3 in those with HBsAg persistence (P = .004). Conclusions HBsAg loss occurs in about 10% of those with chronic HBV infection. Being Hispanic, having AIDS at baseline, having an injection drug use history, and having HBeAg-negative status at baseline predicted the likelihood of HBsAg loss. Immune restoration may be a mechanism through which HBsAg loss occurs in HIV patients. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
6. The risk of depression among racially diverse people living with HIV: the impact of HIV viral suppression.
- Author
-
Jain, Mamta K., Li, Xilong, Adams-Huet, Beverley, Tiruneh, Yordanos M., Luque, Amneris E., Duarte, Piper, Trombello, Joseph M., and Nijhawan, Ank E.
- Subjects
- *
MENTAL depression risk factors , *HIV-positive persons , *CROSS-sectional method , *VIRAL load , *MULTIVARIATE analysis , *MULTIPLE regression analysis , *INTRAVENOUS drug abuse , *RETROSPECTIVE studies , *RACE , *RISK assessment , *SEX distribution , *QUESTIONNAIRES , *DESCRIPTIVE statistics , *MEN who have sex with men - Abstract
Understanding the correlates of depression in HIV patients can help identify groups whose members are at increased risk for depression. We conducted a cross-sectional retrospective study among racially diverse, indigent patients living with HIV (PLWH) who were obtaining care in an urban safety-net hospital system and had completed a Patient Health Questionnaire-9 (PHQ-9) in 2014 or 2015. We collected demographics, HIV risk factors, HIV viral loads, CD4 counts, missed visits, and emergency department (ED) visits. Data from the Substance Abuse and Mental Illness Symptoms Screener (SAMISS) were abstracted. Missing data on substance use and CD4 cell counts were imputed to examine the odds of depression (PHQ-9 ≥ 10) by multivariable analysis for a complete case and sensitivity analysis. Stratified analysis by HIV viral suppression (VS) was used to determine the odds of depression among subgroups. Of the 5126 HIV patients (70.8% male,56.3% Black, 44.6% MSM, 6.0% IDU), 1271 (24.8%) experienced depression (PHQ ≥ 10). In a multivariable logistic model female gender, White race, injection drug use (IDU) or men who have sex with men (MSM) as an HIV risk factor, making ≥1 ED visit, having missed any HIV visit, having AIDS, and having a positive drug screen by SAMISS increased the odds for depression. Those who had achieved HIV VS or received efavirenz had lower odds of depression. Even among those with AIDS, those failing to achieve VS were at increased odds for depression, whereas those achieving VS were not. Moderate to severe depression is prevalent among PLWH. Among those with AIDS, HIV VS modifies the odds of depression. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
7. Role of Inflammatory Biomarkers in the Prevalence and Incidence of Hypertension Among HIV-Positive Participants in the START Trial.
- Author
-
Ghazi, Lama, Baker, Jason V, Sharma, Shweta, Jain, Mamta K, Palfreeman, Adrian, Necsoi, Coca, Murray, Daniel D, Neaton, James D, and Drawz, Paul E
- Subjects
ORTHOSTATIC hypotension ,SYSTOLIC blood pressure ,BODY mass index ,OUTSIDER art ,HYPERTENSION ,HIV-positive persons - Abstract
BACKGROUND The association between hypertension (HTN) and inflammatory biomarkers (interleukin-6 [IL-6] and high-sensitivity C-reactive protein [hsCRP]) in HIV-positive persons with CD4+ count >500 cells/mm
3 is unknown. METHODS We studied HTN in participants of the Strategic Timing of AntiRetroviral Treatment (START) trial of immediate vs. deferred antiretroviral therapy (ART) in HIV-positive, ART naive adults with CD4+ count > 500 cells/mm3 . HTN was defined as having a systolic blood pressure (BP) ≥140 mmHg, a diastolic BP ≥90 mmHg, or using BP-lowering therapy. Logistic and discrete Cox regression models were used to study the association between baseline biomarker levels with prevalent and incident HTN. RESULTS Among 4,249 participants with no history of cardiovascular disease, the median age was 36 years, 55% were nonwhite, and the prevalence of HTN at baseline was 18.9%. After adjustment for race, age, gender, body mass index (BMI), diabetes, smoking, HIV RNA and CD4+ levels, associations of IL-6 and hsCRP with HTN prevalence were not significant (OR per twofold higher:1.10, 95% confidence interval [CI]: 0.99, 1.20 for IL-6 and 1.05, 95% CI: 0.99, 1.10 for hsCRP). Overall incidence of HTN was 6.8 cases/100 person years. In similarly adjusted models, neither IL-6 (Hazard ratios [HR] per twofold higher IL-6 levels: 0.97, 95% CI: 0.88, 1.08) nor hsCRP (HR per twofold higher hsCRP levels: 0.97, 95% CI: 0.92, 1.02) were associated with risk of incident HTN. Associations did not differ by treatment group. Age, race, gender, and BMI were significantly associated with both the prevalence and incidence of HTN. CONCLUSIONS Traditional risk factors and not baseline levels of IL-6 or hsCRP were associated with the prevalence and incidence of HTN in START. [ABSTRACT FROM AUTHOR]- Published
- 2020
- Full Text
- View/download PDF
8. Effect of Patient Navigation With or Without Financial Incentives on Viral Suppression Among Hospitalized Patients With HIV Infection and Substance Use: A Randomized Clinical Trial.
- Author
-
Metsch, Lisa R., Feaster, Daniel J., Gooden, Lauren, Matheson, Tim, Stitzer, Maxine, Das, Moupali, Jain, Mamta K., Rodriguez, Allan E., Armstrong, Wendy S., Lucas, Gregory M., Nijhawan, Ank E., Drainoni, Mari-Lynn, Herrera, Patricia, Vergara-Rodriguez, Pamela, Jacobson, Jeffrey M., Mugavero, Michael J., Sullivan, Meg, Daar, Eric S., McMahon, Deborah K., and Ferris, David C.
- Subjects
HIV infection risk factors ,HIV-positive persons ,HOSPITAL patients ,VIRAL load ,MEDICAL case management ,RANDOMIZED controlled trials ,DISEASES ,SUBSTANCE abuse ,HIV infection complications ,HIV infection epidemiology ,COMPARATIVE studies ,ECONOMICS ,HIV ,HIV infections ,RESEARCH methodology ,MEDICAL cooperation ,MOTIVATION (Psychology) ,RESEARCH ,RESEARCH funding ,EVALUATION research ,SOCIAL services case management ,MOTIVATIONAL interviewing ,TREATMENT effectiveness ,PATIENT-centered care ,ANTI-HIV agents ,DISEASE complications - Abstract
Importance: Substance use is a major driver of the HIV epidemic and is associated with poor HIV care outcomes. Patient navigation (care coordination with case management) and the use of financial incentives for achieving predetermined outcomes are interventions increasingly promoted to engage patients in substance use disorders treatment and HIV care, but there is little evidence for their efficacy in improving HIV-1 viral suppression rates.Objective: To assess the effect of a structured patient navigation intervention with or without financial incentives to improve HIV-1 viral suppression rates among patients with elevated HIV-1 viral loads and substance use recruited as hospital inpatients.Design, Setting, and Participants: From July 2012 through January 2014, 801 patients with HIV infection and substance use from 11 hospitals across the United States were randomly assigned to receive patient navigation alone (n = 266), patient navigation plus financial incentives (n = 271), or treatment as usual (n = 264). HIV-1 plasma viral load was measured at baseline and at 6 and 12 months.Interventions: Patient navigation included up to 11 sessions of care coordination with case management and motivational interviewing techniques over 6 months. Financial incentives (up to $1160) were provided for achieving targeted behaviors aimed at reducing substance use, increasing engagement in HIV care, and improving HIV outcomes. Treatment as usual was the standard practice at each hospital for linking hospitalized patients to outpatient HIV care and substance use disorders treatment.Main Outcomes and Measures: The primary outcome was HIV viral suppression (≤200 copies/mL) relative to viral nonsuppression or death at the 12-month follow-up.Results: Of 801 patients randomized, 261 (32.6%) were women (mean [SD] age, 44.6 years [10.0 years]). There were no differences in rates of HIV viral suppression versus nonsuppression or death among the 3 groups at 12 months. Eighty-five of 249 patients (34.1%) in the usual-treatment group experienced treatment success compared with 89 of 249 patients (35.7%) in the navigation-only group for a treatment difference of 1.6% (95% CI, -6.8% to 10.0%; P = .80) and compared with 98 of 254 patients (38.6%) in the navigation-plus-incentives group for a treatment difference of 4.5% (95% CI -4.0% to 12.8%; P = .68). The treatment difference between the navigation-only and the navigation-plus-incentives group was -2.8% (95% CI, -11.3% to 5.6%; P = .68).Conclusions and Relevance: Among hospitalized patients with HIV infection and substance use, patient navigation with or without financial incentives did not have a beneficial effect on HIV viral suppression relative to nonsuppression or death at 12 months vs treatment as usual. These findings do not support these interventions in this setting.Trial Registration: clinicaltrials.gov Identifier: NCT01612169. [ABSTRACT FROM AUTHOR]- Published
- 2016
- Full Text
- View/download PDF
9. Half of 30-Day Hospital Readmissions Among HIV-Infected Patients Are Potentially Preventable.
- Author
-
Nijhawan, Ank E., Kitchell, Ellen, Etherton, Sarah Shelby, Duarte, Piper, Halm, Ethan A., and Jain, Mamta K.
- Subjects
DRUGS ,EMERGENCY medical services ,HEALTH care teams ,HIV-positive persons ,MULTIVARIATE analysis ,PATIENT compliance ,PREVENTIVE health services ,RESEARCH funding ,STATISTICS ,RETROSPECTIVE studies ,PATIENT readmissions ,DATA analysis software ,DESCRIPTIVE statistics ,ODDS ratio - Abstract
Thirty-day readmission rates, a widely utilized quality metric, are high among HIV-infected individuals. However, it is unknown how many 30-day readmissions are preventable, especially in HIV patients, who have been excluded from prior potentially preventable readmission analyses. We used electronic medical records to identify all readmissions within 30 days of discharge among HIV patients hospitalized at a large urban safety net hospital in 2011. Two independent reviewers assessed whether readmissions were potentially preventable using both published criteria and detailed chart review, how readmissions might have been prevented, and the phase of care deemed suboptimal (inpatient care, discharge planning, post-discharge). Of 1137 index admissions, 213 (19%) resulted in 30-day readmissions. These admissions occurred among 930 unique HIV patients, with 130 individuals (14%) experiencing 30-day readmissions. Of these 130, about half were determined to be potentially preventable using published criteria (53%) or implicit chart review (48%). Not taking antiretroviral therapy (ART) greatly increased the odds of a preventable readmission (OR 5.9, CI:2.4-14.8). Most of the preventable causes of readmission were attributed to suboptimal care during the index hospitalization. Half of 30-day readmission in HIV patients are potentially preventable. Increased focus on early ART initiation, adherence counseling, management of chronic conditions, and appropriate timing of discharge may help reduce readmissions in this vulnerable population. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
10. Suppression of HBV by Tenofovir in HBV/HIV Coinfected Patients: A Systematic Review and Meta-Analysis.
- Author
-
Price, Huw, Dunn, David, Pillay, Deenan, Bani-Sadr, Firouze, de Vries-Sluijs, Theodora, Jain, Mamta K., Kuzushita, Noriyoshi, Mauss, Stefan, Núñez, Marina, Nüesch, Reto, Peters, Marion, Reiberger, Thomas, Stephan, Christoph, Tan, Lionel, and Gilson, Richard
- Subjects
IMMUNOSUPPRESSION ,HEPATITIS B treatment ,HIV infections ,THERAPEUTICS ,HIV-positive persons ,SYSTEMATIC reviews ,ANTIRETROVIRAL agents ,TENOFOVIR - Abstract
Background: Hepatitis B coinfection is common in HIV-positive individuals and as antiretroviral therapy has made death due to AIDS less common, hepatitis has become increasingly important. Several drugs are available to treat hepatitis B. The most potent and the one with the lowest risk of resistance appears to be tenofovir (TDF). However there are several questions that remain unanswered regarding the use of TDF, including the proportion of patients that achieves suppression of HBV viral load and over what time, whether suppression is durable and whether prior treatment with other HBV-active drugs such as lamivudine, compromises the efficacy of TDF due to possible selection of resistant HBV strains. Methods: A systematic review and meta-analysis following PRISMA guidelines and using multilevel mixed effects logistic regression, stratified by prior and/or concomitant use of lamivudine and/or emtricitabine. Results: Data was available from 23 studies including 550 HBV/HIV coinfected patients treated with TDF. Follow up was for up to seven years but to ensure sufficient power the data analyses were limited to three years. The overall proportion achieving suppression of HBV replication was 57.4%, 79.0% and 85.6% at one, two and three years, respectively. No effect of prior or concomitant 3TC/FTC was shown. Virological rebound on TDF treatment was rare. Interpretation: TDF suppresses HBV to undetectable levels in the majority of HBV/HIV coinfected patients with the proportion fully suppressed continuing to increase during continuous treatment. Prior treatment with 3TC/FTC does not compromise efficacy of TDF treatment. The use of combination treatment with 3TC/FTC offers no significant benefit over TDF alone. [ABSTRACT FROM AUTHOR]
- Published
- 2013
- Full Text
- View/download PDF
11. Pegylated Interferon and Ribavirin Promote Early Evolution of Nonstructural 5A Protein in Individuals with Hepatitis C Who Demonstrate a Response to Treatment.
- Author
-
Jain, Mamta K., He-Jun Yuan, Adams-Huet, Beverley, Reeck, Amanda, Shelton, Janel, Attar, Nahid, Song Zhang, Neumann, Avidan U., Carney, David S., Gale, Jr., Michael, and William M. Lee
- Subjects
- *
HIV-positive persons , *RIBAVIRIN , *INTERFERONS , *GENETIC polymorphisms , *HEPATITIS C virus , *ANTIVIRAL agents , *GENETIC research , *THERAPEUTICS , *LIVER diseases - Abstract
Background. Hepatitis C virus (HCV) quasispecies diversity is more likely to affect early viral decline during treatment of hepatitis C than is having human immunodeficiency virus (HIV) infection.We evaluated the influence of HCV therapy on changes in the nonstructural 5A (NS5A) protein. Methods. Fifteen patients with HCV genotype 1 infection with or without HIV infection were recruited for the present study, and the decrease in the HCV RNA level was measured at early time points. The evolution of HCV NS5A quasispecies within the first week was analyzed by comparing the clones observed at later times in the study with the baseline consensus sequence of individual patients. The response to therapy was defined as an early response (ER; ie, an HCV RNA level <615 IU/mL at week 4) or a slow response (SR; ie, a detectable HCV RNA level at week 4). Results. HIV infection did not affect early viral kinetics. At baseline, lower diversity was seen in NS5A and in the amino and carboxyl termini of patients with an ER, compared with those with an SR. Rapid evolution of the NS5A genetic region occurred in patients with an ER (P = .01) but not in those with an SR (P = .73). The evolution was the result of an increase in the number of amino acid substitutions in the carboxyl region (P = .02) in patients with an ER. Conclusions. Selective pressure appears to result in more-marked changes in individuals with an ER than in those with an SR. The carboxyl terminus was subject to the most change and may be an important determinant of phenotypic resistance to interferon-based therapy. [ABSTRACT FROM AUTHOR]
- Published
- 2009
- Full Text
- View/download PDF
12. Changes in Mortality Related to Human Immunodeficiency Virus Infection: Comparative Analysis of Inpatient Deaths in 1995 and in 1999-2000.
- Author
-
Jain, Mamta K., Skiest, Daniel J., Cloud, Jeff W., Jain, Charu L., Burns, Dennis, and Berggren, Ruth E.
- Subjects
- *
HIV-positive persons , *MORTALITY - Abstract
Presents a retrospective chart review of HIV-infected patients who died in 1995 and in 1999-2000. Increase in the proportion of patients who died from an illness not related to AIDS; Leading cause of death; Main reasons why patients were not receiving antiretroviral therapy.
- Published
- 2003
- Full Text
- View/download PDF
13. Mortality in Patients Coinfected with Hepatitis B Virus and HIV: Could Antiretroviral Therapy Make a Difference?
- Author
-
Jain, Mamta K.
- Subjects
- *
MEDICAL research , *HEPATITIS B prevention , *AIDS prevention , *HIV-positive persons , *MORTALITY , *VACCINATION - Abstract
In this article the author discusses the study conducted by G. K. Nikolopoulos and colleagues that examines the impact of hepatitis B virus (HBV) infection on the progression of AIDS and mortality in HIV-infected individuals. He highlights the significance of the study which establishes that HBV is associated with an excess risk of all-cause mortality. He also cites the significance of effective vaccination for the prevention of HBVin HIV-infected persons.
- Published
- 2009
- Full Text
- View/download PDF
14. Presentation and outcome of hepatocellular carcinoma in HIV-infected patients: A U.S.–Canadian multicenter study
- Author
-
Bräu, Norbert, Fox, Rena K., Xiao, Peiying, Marks, Kristen, Naqvi, Zeenat, Taylor, Lynn E., Trikha, Anita, Sherman, Morris, Sulkowski, Mark S., Dieterich, Douglas T., Rigsby, Michael O., Wright, Teresa L., Hernandez, Maria D., Jain, Mamta K., Khatri, Gajendra K., Sterling, Richard K., Bonacini, Maurizio, Martyn, Catherine A., Aytaman, Ayse, and Llovet, Josep M.
- Subjects
- *
HIV infections , *HIV-positive persons , *LIVER cancer , *HEALTH outcome assessment - Abstract
Background/Aims: HIV-infected patients now live longer and often have complications of liver disease, especially with hepatitis B or C virus coinfection. Limited data are available on those with hepatocellular carcinoma (HCC). Methods: A retrospective analysis from 1992 to 2005 in 6 centers identified 63 HIV-infected HCC patients. Controls were 226 consecutive HIV-negative HCC patients from four sites. Results: HIV-positive patients were younger than controls (52 vs. 64years, p <0.001), more commonly had chronic hepatitis B or C (97% vs. 73%, p <0.001), were more frequently symptomatic (51% vs. 38%, p =0.048), had a higher median alfa-fetoprotein level (227 vs. 51 ng/ml, p =0.005), but a similar mean Child–Turcotte–Pugh score (7.0 vs. 7.5, p =0.05) and HCC staging score (Barcelona-Clínic-Liver-Cancer stages C+D in 50% vs. 58%, p =0.24). HCC developed faster in HIV/HCV-coinfected than in HCV-monoinfected patients (mean, 26 vs. 34years after HCV infection, p =0.002). HIV-positive patients received proven therapy more often (48% vs. 31%, p =0.017), but median survival was similar (6.9 vs. 7.5 months, p =0.44). Independent factors predicting survival were symptomatic presentation (hazard ratio [HR], 0.437; p <0.001), any proven therapy (HR, 2.19; p <0.001), diagnosis after 01-Jan-2002 (HR, 1.52; p =0.010), Barcelona-Clínic-Liver-Cancer stages C+D (HR, 0.491; p <0.001), AST/ALT⩾2.00 (HR, 0.597; p =0.001), AFP⩾400 ng/mL (HR, 0.55, p =0.003), and platelets⩾100,000/mm3 (HR, 0.651; p =0.012), but not HIV-serostatus (p =0.19). In HIV-infected patients without HCC therapy (n =33), median survival was longer with undetectable HIV RNA (<400copies/mL) than with HIV viremia (6.5 vs. 2.6 months, p =0.013). Conclusions: HIV-positive HCC patients are younger and more frequently symptomatic and infected with HCV or HBV than HIV-negative patients. Tumor staging and survival are similar. In untreated patients, undetectable HIV RNA independently predicts better survival. [Copyright &y& Elsevier]
- Published
- 2007
- Full Text
- View/download PDF
15. Self-efficacy as a mediator of patient navigation interventions to engage persons living with HIV and substance use.
- Author
-
Traynor, Sharleen M., Metsch, Lisa R., Gooden, Lauren, Stitzer, Maxine, Matheson, Tim, Tross, Susan, Carrico, Adam W., Jain, Mamta K., del Rio, Carlos, and Feaster, Daniel J.
- Subjects
- *
SUBSTANCE abuse , *SELF-efficacy , *HIV-positive persons , *HIV , *PATIENT compliance , *DIRECTLY observed therapy , *HIV infection epidemiology , *MOTIVATION (Psychology) , *PSYCHOLOGICAL adjustment testing , *PATIENT-centered care , *BEHAVIOR therapy , *MEDICAL care , *DISEASES - Abstract
Background: People living with HIV who report substance use (PLWH-SU) face many barriers to care, resulting in an increased risk for poor health outcomes and the potential for ongoing disease transmission. This study evaluates the mechanisms by which Patient Navigation (PN) and Contingency Management (CM) interventions may work to address barriers to care and improve HIV outcomes in this population.Methods: Mediation analysis was conducted using data from a randomized, multi-site trial testing PN interventions to improve HIV care outcomes among 801 hospitalized PLHW-SU. Direct and indirect effects of PN and PN + CM were evaluated through five potential mediators-psychosocial conditions, healthcare avoidance, financial hardship, system barriers, and self-efficacy for HIV treatment adherence-on engagement in HIV care and viral suppression.Results: The PN + CM intervention had an indirect effect on improving engagement in HIV care at 6 months by increasing self-efficacy for HIV treatment adherence (β = 0.042, 95% CI = 0.008, 0.086). PN + CM also led to increases in viral suppression at 6 months (β = 0.090, 95% CI = 0.023, 0.168) and 12 months (β = 0.069, 95% CI = 0.009, 0.129) via increases in self-efficacy, although the direct effects were not significant. No mediating effects were observed for PN alone.Conclusion: PN + CM interventions for PLWH-SU can increase an individual's self-efficacy for HIV treatment adherence, which in turn improves engagement in care at 6 months and may contribute to viral suppression over 12 months. Building self-efficacy may be a key factor in the success of such interventions and should be considered as a primary goal of PN + CM in practice. [ABSTRACT FROM AUTHOR]- Published
- 2021
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.